ZoAnn E. Dreyer
YOU?
Author Swipe
View article: Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge
Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge Open
We present 2 diagnostically challenging cases of pediatric/adolescent relapsed/refractory aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) within the spectrum of Burkitt lymphoma and diffuse large B-cell lymphoma and illustrate the di…
View article: Minimal residual disease predicts outcomes in <i>KMT2A</i>‐rearranged but not <i>KMT2A</i>‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Minimal residual disease predicts outcomes in <i>KMT2A</i>‐rearranged but not <i>KMT2A</i>‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631 Open
We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]‐specific methyltransferase 2A)‐rearranged and 58 with KMT2A ‐germline acute lymphoblastic leukemia …
View article: Supplementary Tables and Figures from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Supplementary Tables and Figures from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients Open
Supplementary Tables and Figures
View article: Data from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Data from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients Open
Purpose: Methotrexate chemotherapy can be associated with neurologic complications during therapy and long-term neurologic deficits. This study evaluated demographic and clinical factors associated with incidence of methotrexate neurotoxic…
View article: Data from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Data from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients Open
Purpose: Methotrexate chemotherapy can be associated with neurologic complications during therapy and long-term neurologic deficits. This study evaluated demographic and clinical factors associated with incidence of methotrexate neurotoxic…
View article: Supplementary Tables and Figures from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Supplementary Tables and Figures from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients Open
Supplementary Tables and Figures
View article: Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience Open
The BCL-2 inhibitor venetoclax improves survival for adult patients with acute myeloid leukemia (AML) in combination with lower-intensity therapies, but its benefit in pediatric patients with AML remains unclear. We retrospectively reviewe…
View article: <i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children’s Oncology Group P9407 trial study
<i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children’s Oncology Group P9407 trial study Open
Not available.
View article: Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial Open
Not available.
View article: Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma Open
Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed–Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of…
View article: Association of <i>GSTM1</i> null variant with anthracycline‐related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report
Association of <i>GSTM1</i> null variant with anthracycline‐related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report Open
Background Anthracycline‐related cardiomyopathy is a leading cause of late morbidity in childhood cancer survivors. Glutathione S‐transferases (GSTs) are a class of phase II detoxification enzymes that facilitate the elimination of anthrac…
View article: Early Lifestyle Intervention for Obesity Prevention in Pediatric Survivors of Acute Lymphoblastic Leukemia
Early Lifestyle Intervention for Obesity Prevention in Pediatric Survivors of Acute Lymphoblastic Leukemia Open
Patients with pediatric acute lymphoblastic leukemia (ALL) experience rapid weight gain during treatment and increases in weight are maintained throughout treatment and beyond. Without prompt interventions, altered dietary and physical act…
View article: Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients Open
Purpose: Methotrexate chemotherapy can be associated with neurologic complications during therapy and long-term neurologic deficits. This study evaluated demographic and clinical factors associated with incidence of methotrexate neurotoxic…
View article: PDCT-22. GENOME-WIDE DISCOVERY OF NOVEL SUSCEPTIBILITY POLYMORPHISMS FOR TREATMENT-ASSOCIATED HYPOTHYROIDISM IN PEDIATRIC MEDULLOBLASTOMA
PDCT-22. GENOME-WIDE DISCOVERY OF NOVEL SUSCEPTIBILITY POLYMORPHISMS FOR TREATMENT-ASSOCIATED HYPOTHYROIDISM IN PEDIATRIC MEDULLOBLASTOMA Open
Pediatric medulloblastoma patients are at high risk of developing hypothyroidism after craniospinal radiotherapy (CSI). We investigated the role of genetic variation on hypothyroidism susceptibility in children and adolescents with medullo…
View article: Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group Open
Background Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparagin…
View article: Developing a Web-Based Weight Management Program for Childhood Cancer Survivors: Rationale and Methods
Developing a Web-Based Weight Management Program for Childhood Cancer Survivors: Rationale and Methods Open
Lifestyle interventions are a priority for preventing the early onset of obesity and cardiovascular risk factors in childhood cancer survivors. Intervention programs need to meet survivors' targeted behavioral needs, address specific barri…
View article: <i>CELF4</i> Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study
<i>CELF4</i> Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study Open
Purpose Interindividual variability in the dose-dependent association between anthracyclines and cardiomyopathy suggests that genetic susceptibility could play a role. The current study uses an agnostic approach to identify genetic variant…